An Asian study to evaluate efficacy and safety of oral enzalutamide in progressive metastatic prostate cancer participants

Trial Identifier: 9785-CL-0232
Sponsor: Astellas Pharma Inc.
Start Date: April 2014
Primary Completion Date: September 2015
Study Completion Date: July 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Hangzhou, China
China Shanghai, China
China Soochow, China
China Tianjin, China
China Wenzhou, China
China Wu Han, China
China Xi'an, China
Hong Kong Hong Kong, Hong Kong
Korea (Republic of) Anyang, Korea (Republic of)
Korea (Republic of) Busan, Korea (Republic of)
Korea (Republic of) Cheongju, Korea (Republic of)
Korea (Republic of) Daegu, Korea (Republic of)
Korea (Republic of) Daejeon, Korea (Republic of)
Korea (Republic of) Incheon, Korea (Republic of)
Korea (Republic of) Seongnam-si, Korea (Republic of)
Korea (Republic of) Seoul, Korea (Republic of)
Taiwan, Province of China Kaohsiung, Taiwan, Province of China
Taiwan, Province of China Taichung, Taiwan, Province of China
Taiwan, Province of China Tainan, Taiwan, Province of China
Taiwan, Province of China Taipei, Taiwan, Province of China
Taiwan, Province of China Taoyuan County, Taiwan, Province of China